NewcelX Ltd. successfully completed a pre-IND meeting with the FDA, receiving positive feedback on its development plan for NCEL-101, a stem-cell-derived therapy for type 1 diabetes. The FDA's support allows NewcelX to proceed toward clinical trials combining NCEL-101 with Eledon Pharmaceuticals' immunomodulatory drug, tegoprubart. This combination aims to improve islet cell transplant survival and function, potentially offering a transformative treatment for type 1 diabetes. The next steps involve IND-enabling activities and clinical trial initiation, marking a key milestone in developing a potential functional cure for the disease.
Glass has celebrated two years of transforming U.S. federal procurement through its AI-native G-Commerce platform, part of the General Services Administration’s Commercial Platforms Program. The platform now serves over 50,000 federal users across 44...
Swords to Plowshares received a $750,000 grant from The Home Depot Foundation to rehabilitate 1035 Van Ness Avenue in San Francisco into 124 permanent supportive homes for veterans experiencing or at risk of homelessness. This $44 million project con...
ThoughtSpot has been recognized as a Leader in Gartner's 2026 Magic Quadrant for Analytics and Business Intelligence Platforms, highlighting its innovation in AI-powered analytics and enterprise intelligence. The company’s Agentic Analytics platform ...
WhiteBIT, Europe's largest crypto exchange by traffic, has introduced TradeFi, a new trading category that allows users to trade traditional financial instruments such as commodities, stocks, and ETFs through perpetual futures contracts within the cr...
Velosio, a leading Microsoft partner, acquired Kopis and Acuitas to enhance its Azure, business applications, and AI services. Kopis brings over 25 years of experience in custom software and Azure solutions, while Acuitas adds deep expertise in Micro...
